FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness is a research paper published in Alzheimer s & Dementia (2023). On theSindex it has a DataRank of 0. It has been cited 43 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIA NIH HHS
Grant: P30 AG066512
NIA NIH HHS
Grant: R01 AG062572
NINDS NIH HHS
Grant: R01 NS104127
NIA NIH HHS
Grant: P01 AG060882
UK Research and Innovation
Grant: G0400074
Support for Newcastle Brain Tissue Bank
National Institutes of Health
Grant: 1P30AG066512-01
Alzheimer's Disease Research Center
National Institutes of Health
Grant: 1R01NS104127-01A1
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors
FWCI
3.99
Citation Percentile
1.0%
Influential Citations
1
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals